In this issue of
Thoracic Surgery Clinics, guest editors Drs. Brendon M. Stiles and Tamar B. Nobel bring their considerable expertise to the topic of
Advances in Systemic Therapy for Lung Cancer. Recent advances in systemic therapies, marked by ongoing clinical trials and new drug approvals, have revolutionized the treatment landscape, offering new hope for patients with lung cancer. This issue features articles by top experts who explore various topics including novel neoadjuvant and adjuvant clinical trials that could redefine standard care protocols.
- Contains 13 relevant, practice-oriented topics including neoadjuvant immunotherapy alone; neoadjuvant chemotherapy and immunotherapy; adjuvant immunotherapy; update on biomarkers and drug approvals for patients with stage IV NSCLC; role of surgery for patients with metastatic NSCLC; and more
- Provides in-depth articles on advances in systemic therapy for lung cancer, offering actionable insights for clinical practice
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews
Neoadjuvant Immunotherapy
Neoadjuvant Chemoimmunotherapy
Neoadjuvant Tyrosine Kinase Inhibitors
Surgical Challenges After Neoadjuvant Therapy
Adjuvant Immunotherapy in Lung Cancer: Foundational Successes and Future
Directions
The Evolving Role of Adjuvant TKI in Lung Cancer: From Historical Trials to
Future Strategies National Cancer Center Hospital East, Japan
Neoadjuvant, Adjuvant, or Both? Optimizing Perioperative Systemic Therapy in
Lung Cancer
Adding Immunotherapy and Targeted Therapy to Chemoradiotherapy for Non-small
Cell Lung Cancer
Update on Neoadjuvant and Adjuvant Trials
Advances in Systemic Therapy for Lung Cancer: Update on Biomarkers and Novel
Drugs for Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC)
Role of Surgery for Patients with Metastatic Non-small Cell Lung Cancer
